ArticleDiscover oncology2026
BET1 serves as a prognostic indicator and promotes cancer proliferation in glioblastoma multiforme.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BET1 encodes a Golgi-associated membrane protein involved in vesicular transport from the endoplasmic reticulum (ER) to the Golgi apparatus. While the role of BET1 in cancer development remains poorly understood, its function in glioblastoma multiforme (GBM) has not been systematically investigated. In this study, we found that 15 out of 33 cancer types showed significant differential BET1 expression between tumor and normal tissues. Furthermore, survival analysis identified BET1 as an independent prognostic factor in GBM. Additional analyses revealed correlations between BET1 expression and the infiltration of immune cells, such as Tregs and CD4 + T cells, in GBM. Moreover, BET1 knockdown in glioblastoma cells reduced their proliferation and migration capacities. This study provides a comprehensive analysis of BET1, thereby advancing our understanding of its oncogenic potential in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.